RHO-adRP(HG301)

        nAMD(HG202)

        MDS(HG204)

        RPE65-IRDs(HG004)

        DMD(HG302)

        HuidaGene Therapeutics Announces IND Active for the Multinational Trial of HG004 to Treat Inherited Blindness

        HuidaGene Announces IND Approval Of The First China Multinational Master Protocol of HG004 By China NMPA

        HuidaGene Appoints New Members to the Scientific Advisory Board

        HuidaGene Announces Completion of First Patient Enrollment in its Ophthalmic Gene Therapy Candidate HG004 IIT Clinical Trials

        Statement: English name changed from "HuiGene Therapeutics Co., Ltd." to "HuidaGene Therapeutics Co., Ltd.e "

        Engineered high-fidelity Cas13 variants with minimal collateral RNA targeting

        HuidaGene team of scientists collaborate to discover potential new treatment for Duchenne muscular dystrophy

        Huidagene Therapeutics Announces 19 Presentations Highlighting Advances in its Gene Therapy Technology Platforms at the 2023 ASGCT Annual Meeting

        HuidaGene Therapeutics Appoints Alvin Luk as Chief Executive Officer

        NSR｜HuidaGene's Yang Hui team pioneers disruptive guanine (G) base editor

         HuidaGene and Kactus Announce Strategic Collaboration and License Agreement to Promote Commercialization of Next-Generation Gene Editing Enzyme, hfCas12Max®

        HuidaGene Therapeutics Receives FDA Rare Pediatric Disease Designation for HG004 to Treat Inherited Blindness

        HuidaGene Therapeutics Announces First Patient Dosed Of The World's First Novel CRISPR/Cas13 RNA-Editing Therapy HG202 For Neovascular Age-related Macular Degeneration

        HuidaGene Showcases Gene-Editing Based Medicine for Neurological Disease at Japan Society of Gene and Cell Therapy 2023 Annual Meeting

        HuidaGene Therapeutics Announces 13 Presentations at the Upcoming European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

        HuidaGene Therapeutics Announces Last Patient Dosed in Clinical Trial of HG004 for the Treatment of Leber Congenital Amaurosis

        U.S. FDA Awards Both Rare Pediatric Disease and Orphan Drug Designations to HG204, a CRISPR RNA-editing Therapy, for the Treatment of MECP2 Duplication Syndrome

        HuidaGene Therapeutics to Attend BIO-Europe Fall Conference in Munich for Actively Expanding Global Collaboration

        HuidaGene Therapeutics Announces First Patient Dosed in Multnational Phase 1/2 Trial of HG004 for Inherited Blindness

        HuidaGene Announces Rare Pediatric Drug Designation Granted to HG302, A Novel CRISPR DNA-editing Therapy, for the Treatment of Duchenne Muscular Dystrophy

        HuidaGene Receives Orphan Drug Designation from FDA for HG302 for the Potential Treatment of Duchenne Muscular Dystrophy after Receiving Rare Pediatric Drug Designation

        HuidaGene's Sixteen Abstracts Highlight the Strength of the Pipeline and Platform to Advance Genetic Medicines at the 2024 ASGCT Annual Meeting

        HuidaGene Orally Presents Data Highlighting Strength of Ophthalmology Portfolio at the 2024 Association for Research in Visual and Ophthalmology Annual Meeting

        FDA Awards Orphan Drug and Rare Pediatric Disease Designations to the World’s First Cas13X RNA Base-editing Therapy for the Treatment of Congenital Hearing Loss

        HuidaGene Therapeutics to Open Up the First CRISPR MEDiCiNE European Conference

         HuidaGene Therapeutics Receives European Medicines Agency Orphan Designation for HG204 to Treat MECP2 Duplication Syndrome

        HuidaGene and Synthego Announce Licensing Agreement on Next-Generation Gene Editing Enzyme, hfCas12Max

        HuidaGene Therapeutics to Attend 2024 BIO International Convention in California for Actively Expanding Global Collaboration

        NovoCrops and HuidaGene enter licensing partnership to expedite gene editing crop development

        HuidaGene to Highlight Latest Advances in Retina Portfolio at the European Society of Retina Specialists (EURETINA) 2024 Annual Meeting

        HuidaGene Therapeutics Announces the Appointment of Dr. Xin Zhang as Chief Operations Officer and Chief Medical Officer to Further Strengthen the Management Team

        HuidaGene Presents Late-Breaking Data at World Muscle Society 2024 Demonstrating HG302 CRISPR/hfCas12Max DNA-Editing Therapy for Duchenne Muscular Dystrophy to Support M.U.S.C.L.E. Clinical Trial

        HuidaGene Therapeutics Announces Eleven Presentations at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress

        HuidaGene Therapeutics to Attend BIO-Europe Fall 2024 to Expand Global Collaborations in Genome Medicines

        HuidaGene Therapeutics Appoints TJ Cradick, PhD as Chief Technology Officer to Lead Delivery Science and Genome Editing Innovations

        HuidaGene Therapeutics Receives the First-Ever FDA Clearance of CRISPR/Cas13 RNA-Editing HG202 for Macular Degeneration

        HuidaGene Therapeutics Announced First Patient Dosed in the HERO Clinical Trial of HG204 for MECP2 Duplication Syndrome

        HuidaGene Therapeutics Initiates M.U.S.C.L.E. Clinical Trial of HG302 for Duchenne Muscular Dystrophy and Completes First Patient Dosed

        HuidaGene Therapeutics Announces Landmark Publication in Nature Neuroscience Highlighting HG204’s Potential as First RNA-editing Therapy for MECP2 Duplication Syndrom